Affiliation:
1. Department of Stomatology, Changzhi Second People’s Hospital Affiliated to Changzhi Medical College, Changzhi, PR China
2. Department of Stomatology, Shanxi Provincial People’s Hospital, Taiyuan, PR China
3. Department of Stomatology, Heji Hospital Affiliated to Changzhi Medical College, Changzhi, PR China
4. Heilongjiang University of Chinese Medicine, Harbin, PR China.
Abstract
This study explored the mechanism of Huangbai liniment (HB) for the treatment of oral lichen planus (OLP) through network pharmacology and molecular docking techniques. The study identified HB’ active ingredients, therapeutic targets for OLP, and associated signaling pathways. The chemical composition of HB was screened using the HERB database. The disease targets of OLP were obtained through the GeneCards and OMIM databases. A protein–protein interactions network was constructed with the String platform. Topological analysis was performed using Cytoscape software to identify core targets. Gene ontology and Kyoto encyclopedia of genes and genomes pathway enrichment analysis were performed using the Hiplot database, and the active ingredients and core targets were verified by molecular docking. Date analysis showed that the active composition of HB in the treatment of OLP were quercetin, wogonin, kaempferol, and luteolin. This survey identified 10 potential therapeutic targets, including TNF, CXCL8, IL-6, IL1B, PIK3R1, ESR1, JUN, AKT1, PIK3CA, and CTNNB1. Molecular docking revealed stable interactions between OLP’ key targets and HB. These key targets were predominantly involved in the PI3K–Akt signaling pathway, AGE–RAGE signaling pathway, TNF signaling pathway, and HIF-1 signaling pathway. HB plays a crucial role in the treatment of OLP, acting on multiple targets and pathways, particularly the PI3K–Akt signaling pathway. It regulated biological processes like the proliferation of epithelial cells and lymphocytes and mediates the expression of transcription factors, cytokines, and chemokines. Therefore, this study provides a theoretical basis for the clinical trial and application of HB in the therapy of OLP.
Publisher
Ovid Technologies (Wolters Kluwer Health)